1
|
Ryan PC, Santis A, Vanderkloot E, Bhatti M, Caddle S, Ellis M, Grimes A, Silverman S, Soderstrom E, Stone C, Takoudes A, Tulay P, Wright S. The potential for carbon dioxide removal by enhanced rock weathering in the tropics: An evaluation of Costa Rica. Sci Total Environ 2024; 927:172053. [PMID: 38556010 DOI: 10.1016/j.scitotenv.2024.172053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 03/20/2024] [Accepted: 03/26/2024] [Indexed: 04/02/2024]
Abstract
Tropical environments show great potential to sequester CO2 by enhanced rock weathering (ERW) of powdered mafic rocks applied to agricultural fields. This study seeks to assess carbon dioxide reduction (CDR) potential in the humid tropics (1) by experimental weathering of mafic rock powders in conditions simulating humid tropical soils, and (2) from weathering rates determined from a Holocene tropical soil chronosequence where parent material is andesitic sediments. Experimentally determined weathering rates by leaching of basaltic andesites from Costa Rica (Arenal and Barva) for 50 t ha-1 applications indicate potential sequestration of 2.4 to 4.5 t CO2 ha-1 yr-1, whereas the USGS basalt standard BHVO-1 yields a rate of 11.9 t ha-1 yr-1 (influenced by more mafic composition and finer particle size). The chronosequence indicates a rate of 1.7 t CO2 ha-1 yr-1. The weathering experiment consisted of 0.6 mm of powdered rock applied atop 12 mm of Ultisol at 35 °C. To simulate a tropical soil solution, 100-mL aliquots of a dilute solution of oxalic acid in carbonated DI water were rained onto soils over a 14-day period to simulate soil moisture in the humid tropics. Solutions were collected and analyzed by ICPMS for concentrations of leached cations. A potential ERW scenario for Costa Rica was assessed assuming that one-half of lowland agricultural kaolinitic soils (mainly Ultisols, common crop and pasture soils, excluding protected areas) were to receive 50 t ha-1 of annual or biennial applications of powdered mafic rock. With an experimentally determined humid tropical CDR rate for basaltic andesite (3.5 t ha-1 yr-1) and allowances for carbon costs (e.g. emissions from processing and delivery) that reduce CDR to a net 3.2 t ha-1 yr-1, potential annual CDR of this tropical nation is ∼2-4 million tons, amounting to ∼25-50 % of annual CO2 emissions (mainly from transportation in Costa Rica).
Collapse
Affiliation(s)
- P C Ryan
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA.
| | - A Santis
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - E Vanderkloot
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - M Bhatti
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - S Caddle
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - M Ellis
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - A Grimes
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - S Silverman
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - E Soderstrom
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - C Stone
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - A Takoudes
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - P Tulay
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| | - S Wright
- Department of Earth and Climate Sciences, Middlebury College, 276 Bicentennial Way, Middlebury, VT 05753, USA
| |
Collapse
|
2
|
Daza JF, Cuthbertson BH, Myles PS, Shulman MA, Wijeysundera DN, Wijeysundera DN, Pearse RM, Myles PS, Abbott TEF, Shulman MA, Torres E, Ambosta A, Melo M, Mamdani M, Thorpe KE, Wallace S, Farrington C, Croal BL, Granton JT, Oh P, Thompson B, Hillis G, Beattie WS, Wijeysundera HC, Ellis M, Borg B, Kerridge RK, Douglas J, Brannan J, Pretto J, Godsall MG, Beauchamp N, Allen S, Kennedy A, Wright E, Malherbe J, Ismail H, Riedel B, Melville A, Sivakumar H, Murmane A, Kenchington K, Kirabiyik Y, Gurunathan U, Stonell C, Brunello K, Steele K, Tronstad O, Masel P, Dent A, Smith E, Bodger A, Abolfathi M, Sivalingam P, Hall A, Painter TW, Macklin S, Elliott A, Carrera AM, Terblanche NCS, Pitt S, Samuels J, Wilde C, Leslie K, MacCormick A, Bramley D, Southcott AM, Grant J, Taylor H, Bates S, Towns M, Tippett A, Marshall F, McCartney CJL, Choi S, Somascanthan P, Flores K, Karkouti K, Clarke HA, Jerath A, McCluskey SA, Wasowicz M, Day L, Pazmino-Canizares J, Belliard R, Lee L, Dobson K, Stanbrook M, Hagen K, Campbell D, Short T, Van Der Westhuizen J, Higgie K, Lindsay H, Jang R, Wong C, McAllister D, Ali M, Kumar J, Waymouth E, Kim C, Dimech J, Lorimer M, Tai J, Miller R, Sara R, Collingwood A, Olliff S, Gabriel S, Houston H, Dalley P, Hurford S, Hunt A, Andrews L, Navarra L, Jason-Smith A, Thompson H, McMillan N, Back G. Measurement properties of the WHO Disability Assessment Schedule 2.0 for evaluating functional status after inpatient surgery. Br J Surg 2022; 109:968-976. [PMID: 35929065 DOI: 10.1093/bjs/znac263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/17/2022] [Accepted: 07/08/2022] [Indexed: 11/12/2022]
Abstract
BACKGROUND Expert recommendations propose the WHO Disability Assessment Schedule (WHODAS) 2.0 as a core outcome measure in surgical studies, yet data on its long-term measurement properties remain limited. These were evaluated in a secondary analysis of the Measurement of Exercise Tolerance before Surgery (METS) prospective cohort. METHODS Participants were adults (40 years of age or older) who underwent inpatient non-cardiac surgery. The 12-item WHODAS and EQ-5DTM-3L questionnaires were administered preoperatively (in person) and 1 year postoperatively (by telephone). Responsiveness was characterized using standardized response means (SRMs) and correlation coefficients between change scores. Construct validity was evaluated using correlation coefficients between 1-year scores and comparisons of WHODAS scores across clinically relevant subgroups. RESULTS The analysis included 546 patients. There was moderate correlation between changes in WHODAS and various EQ-5DTM subscales. The strongest correlation was between changes in WHODAS and changes in the functional domains of the EQ-5D-3L-for example, mobility (Spearman's rho 0.40, 95 per cent confidence interval [c.i.] 0.32 to 0.48) and usual activities (rho 0.45, 95 per cent c.i. 0.30 to 0.52). When compared across quartiles of EQ-5D index change, median WHODAS scores followed expected patterns of change. In subgroups with expected functional status changes, the WHODAS SRMs ranged from 'small' to 'large' in the expected directions of change. At 1 year, the WHODAS demonstrated convergence with the EQ-5D-3L functional domains, and good discrimination between patients with expected differences in functional status. CONCLUSION The WHODAS questionnaire has construct validity and responsiveness as a measure of functional status at 1 year after major surgery.
Collapse
Affiliation(s)
- Julian F Daza
- Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.,Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Brian H Cuthbertson
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.,Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Paul S Myles
- Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia
| | - Mark A Shulman
- Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia
| | - Duminda N Wijeysundera
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.,Department of Anesthesia, St. Michael's Hospital, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Kleiner J, Ellis M, Borg B, Nilsen K, Oto T, Levvey B, Snell G. There is No Smoking Gun: LongTerm Lung Transplant (LTx) Outcomes Using Smoking Donors. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
4
|
Lerner S, Malovannaya A, Holt M, Kremers K, Ittman M, Saltzman A, Young M, Anurag M, Kim BJ, Ellis M. Proteogenomic characterization of muscle invasive bladder cancer identifies mechanisms of resistance and potential targets for therapy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01153-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
5
|
Perez-Siles G, Ellis M, Ashe A, Grosz B, Vucic S, Kiernan MC, Morris KA, Reddel SW, Kennerson ML. A Compound Heterozygous Mutation in Calpain 1 Identifies a New Genetic Cause for Spinal Muscular Atrophy Type 4 (SMA4). Front Genet 2022; 12:801253. [PMID: 35126465 PMCID: PMC8807693 DOI: 10.3389/fgene.2021.801253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Accepted: 12/21/2021] [Indexed: 12/27/2022] Open
Abstract
Spinal Muscular Atrophy (SMA) is a heterogeneous group of neuromuscular diseases characterized by degeneration of anterior horn cells of the spinal cord, leading to muscular atrophy and weakness. Although the major cause of SMA is autosomal recessive exon deletions or loss-of-function mutations of survival motor neuron 1 (SMN1) gene, next generation sequencing technologies are increasing the genetic heterogeneity of SMA. SMA type 4 (SMA4) is an adult onset, less severe form of SMA for which genetic and pathogenic causes remain elusive.Whole exome sequencing in a 30-year-old brother and sister with SMA4 identified a compound heterozygous mutation (p. G492R/p. F610C) in calpain-1 (CAPN1). Mutations in CAPN1 have been previously associated with cerebellar ataxia and hereditary spastic paraplegia. Using skin fibroblasts from a patient bearing the p. G492R/p. F610C mutation, we demonstrate reduced levels of CAPN1 protein and protease activity. Functional characterization of the SMA4 fibroblasts revealed no changes in SMN protein levels and subcellular distribution. Additional cellular pathways associated with SMA remain unaffected in the patient fibroblasts, highlighting the tissue specificity of CAPN1 dysfunction in SMA4 pathophysiology. This study provides genetic and functional evidence of CAPN1 as a novel gene for the SMA4 phenotype and expands the phenotype of CAPN1 mutation disorders.
Collapse
Affiliation(s)
- G. Perez-Siles
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
- *Correspondence: G. Perez-Siles , ; M. L. Kennerson,
| | - M. Ellis
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW, Australia
| | - A. Ashe
- Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia
| | - B. Grosz
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - S. Vucic
- Brain and Nerve Research Center, Concord Clinical School, University of Sydney, Sydney, NSW, Australia
| | - M. C. Kiernan
- Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia
- Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
| | - K. A. Morris
- Department of Neurology, Concord Repatriation General Hospital, Sydney, Sydney, NSW, Australia
| | - S. W. Reddel
- Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia
| | - M. L. Kennerson
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
- Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, NSW, Australia
- *Correspondence: G. Perez-Siles , ; M. L. Kennerson,
| |
Collapse
|
6
|
Catapano F, Ellis M, Torelli S, Chambers D, Evangelista T, Leturcq F, Natera-de Benito D, Jimenez-Mallebrera C, Marini-Bettolo C, Charlton R, Stenzel W, Dittmayer C, Schänzer A, Hilton D, Lilleker J, Roncaroli F, Sarkozy A, Muntoni F, Phadke R. DMD - BIOMARKERS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Scaglioni D, Catapano F, Ellis M, Torelli S, Chambers D, Feng L, Husayni S, Malhotra J, Harriman S, Koenig E, Dugar A, Steiner D, Morgan J, Phadke R, Muntoni F. DMD – BIOMARKERS & OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Harding L, Park P, Thorniley M, Ellis M, Reed C, Taylor S, Singleton L, Tolley J, Richardson T. "Always Events® "… just another quality improvement tool … or is it? Radiography (Lond) 2020; 26 Suppl 2:S20-S26. [PMID: 32753259 DOI: 10.1016/j.radi.2020.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 05/18/2020] [Accepted: 06/03/2020] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Always Events® are defined as "those aspects of the care experience that should always occur when patients, their family members or other care partners, and service users interact with health care professionals and the health care system". It is a quality improvement methodology that starts by asking our patients the simple question "what matters to you?" and then through coproduction, works out a way to achieve this. METHODS AND RESULTS This article tells our story and highlights the value of undertaking an Always Event® within the Radiology department at Warrington and Halton Hospitals. It will demonstrate how this approach combines research, an evaluation of findings and implementation of those findings within a very short timeframe. Embedded within the article are comments from our staff, volunteers and patients which reflect upon their experiences, our limitations, the outcomes we achieved and the impact it has had upon our patients and staff. CONCLUSION AND IMPLICATIONS FOR PRACTICE It was important to our patients that they would be informed of how long they would wait for their examination once they booked in at x-ray reception. By undertaking an Always Event® this process is now embedded in our departments everyday activities with over 90% of our patients now being informed of their waiting time. This continued collaboration has really emphasised the value of listening to our patients, and the benefits this can lead to. It has also encouraged a positive research culture within our department (optimisation studies, working with industry, quality projects), helping to progress our profession and resulting in a quality service for our patients.
Collapse
|
9
|
McKenzie H, Martland G, Ellis M, Eccles D, Harris S, Thirdborough S, Copson E, Thomas G. The Immune Microenvironment in Young Patients with Triple Negative Breast Cancer. Clin Oncol (R Coll Radiol) 2020. [DOI: 10.1016/j.clon.2020.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Abbas Y, Abdelkader M, Adams M, Addison A, Advani R, Ahmed T, Alexander V, Alexander V, Alli B, Alvi S, Amiraraghi N, Ashman A, Balakumar R, Bewick J, Bhasker D, Bola S, Bowles P, Campbell N, Can Guru Naidu N, Caton N, Chapman J, Chawdhary G, Cherko M, Coates M, Conroy K, Coyle P, Cozar O, Cresswell M, Dalton L, Danino J, Daultrey C, Davies K, Carrie S, Dick D, Dimitriadis PA, Doddi N, Dowling M, Easto R, Edmiston R, Ellul D, Erskine S, Evans A, Farboud A, Forde C, Fussey J, Gaunt A, Gilchrist J, Gohil R, Gosnell E, Grech Marguerat D, Green R, Grounds R, Hall A, Hardman J, Harris A, Harrison L, Hone R, Hoskison E, Howard J, Ioannidis D, Iqbal I, Janjua N, Jolly K, Kamal S, Kanzara T, Keates N, Kelly A, Khan H, Korampalli T, Kuet M, Kul‐loo P, Lakhani R, Lambert A, Lancer H, Leonard C, Lloyd G, Lowe E, Mair J, Maughan E, Gao C, Mayberry T, McCadden L, McClenaghan F, McKenzie G, Mcleod R, Meghji S, Mian M, Millington A, Mirza O, Mistry S, Molena E, Morris J, Myuran T, Navaratnam A, Noon E, Okonkwo O, Oremule B, Pabla L, Papesch E, Puranik V, Roplekar R, Ross E, Rudd J, Schechter E, Senior A, Sethi N, Sharma S, Sharma R, Shelton F, Sherazi Z, Tahir A, Tikka T, Tkachuk Hlinicanova O, To K, Tse A, Toll E, Ubayasiri K, Unadkat S, Upile N, Vijendren A, Walijee H, Wilkie M, Williams R, Williams M, Wilson G, Wong W, Wong G, Xie C, Yao A, Zhang H, Ellis M, Mehta N, Milinis K, Tikka T, Slovick A, Swords C, Hutson K, Smith ME, Hopkins C, Ng Kee Kwong F. Nasal Packs for Epistaxis: Predictors of Success. Clin Otolaryngol 2020; 45:659-666. [DOI: 10.1111/coa.13555] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 03/08/2020] [Accepted: 04/13/2020] [Indexed: 11/30/2022]
|
11
|
Perez-Siles G, Cutrupi A, Ellis M, Screnci R, Mao D, Uesugi M, Yiu EM, Ryan MM, Choi BO, Nicholson G, Kennerson ML. Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Sci Rep 2020; 10:9262. [PMID: 32504000 PMCID: PMC7275085 DOI: 10.1038/s41598-020-66266-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 05/18/2020] [Indexed: 11/09/2022] Open
Abstract
Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. PDK3 is one of four PDK isoenzymes that regulate the activity of the pyruvate dehydrogenase complex (PDC). The balance between kinases (PDKs) and phosphatases (PDPs) determines the extend of oxidative decarboxylation of pyruvate to generate acetyl CoA, critically linking glycolysis and the energy producing Krebs cycle. We had shown the p.R158H mutation causes hyperactivity of PDK3 and CMTX6 fibroblasts show hyperphosphorylation of PDC, leading to reduced PDC activity and ATP production. In this manuscript we have generated induced pluripotent stem cells (iPSCs) by re-programming CMTX6 fibroblasts (iPSCCMTX6). We also have engineered an isogenic control (iPSCisogenic) and demonstrated that genetic correction of the p.R158H mutation reverses the CMTX6 phenotype. Patient-derived motor neurons (MNCMTX6) show increased phosphorylation of the PDC, energy metabolism defects and mitochondrial abnormalities, including reduced velocity of trafficking mitochondria in the affected axons. Treatment of the MNCMTX6 with a PDK inhibitor reverses PDC hyperphosphorylation and the associated functional deficits founds in the patient motor neurons, demonstrating that the MNCMTX6 and MNisogenic motor neurons provide an excellent neuronal system for compound screening approaches to identify drugs for the treatment of CMTX6.
Collapse
Affiliation(s)
- G Perez-Siles
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia. .,Sydney Medical School, University of Sydney, Sydney, Australia.
| | - A Cutrupi
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia.,Sydney Medical School, University of Sydney, Sydney, Australia
| | - M Ellis
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia
| | - R Screnci
- School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia
| | - D Mao
- Institute for Integrated Cell-Material Sciences and Institute for Chemical Research, Kyoto University, Kyoto, Japan
| | - M Uesugi
- Institute for Integrated Cell-Material Sciences and Institute for Chemical Research, Kyoto University, Kyoto, Japan
| | - Eppie M Yiu
- Department of Neurology, Royal Children's Hospital, Flemington Road, Parkville, VIC, Australia.,Neuroscience Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.,Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia
| | - Monique M Ryan
- Department of Neurology, Royal Children's Hospital, Flemington Road, Parkville, VIC, Australia.,Neuroscience Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.,Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia
| | - B O Choi
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - G Nicholson
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia.,Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia
| | - M L Kennerson
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia. .,Sydney Medical School, University of Sydney, Sydney, Australia. .,Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia.
| |
Collapse
|
12
|
McMurrich W, Peters A, Ellis M, Shalaby H, Baer G, MacDonald D, McKinley JC. MIS Distal Metatarsal Metaphyseal Osteotomy in the treatment of metatarsalgia: MOXFQ patient reported outcomes. Foot (Edinb) 2020; 43:101661. [PMID: 32120285 DOI: 10.1016/j.foot.2019.101661] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 11/05/2019] [Accepted: 11/14/2019] [Indexed: 02/04/2023]
Abstract
INTRODUCTION The aim of this paper is to present validated patient reported outcomes for MIS Distal Metatarsal Metaphyseal Osteotomy (DMMO) in the treatment of metatarsalgia. The study aims to evaluate the DMMO procedure, report patient satisfaction with the operated foot and report any complications of this procedure. PATIENTS AND METHODS Between 2014 and 2016, patients who had failed conservative treatment for metatarsalgia were identified in the orthopaedic outpatient clinic. Twenty four consecutive patients requiring DMMO plus/minus toe straightening were prospectively studied. Patients requiring additional procedures at the time of surgery were excluded. Patients completed the validated Manchester-Oxford Foot Questionnaire (MOXFQ) three weeks pre-operatively and 1 year postoperatively. The MOXFQ results were analysed using Paired t-tests. A supplementary question was asked regarding patient satisfaction with the operated foot. RESULTS There were 20 women and 4 men with a mean age of 64 years (sd 8.6). Statistically significant differences were found between the pre and postoperative MOXFQ. The postoperative MOXFQ score demonstrated a poorer result for two patients, no change for two patients and improvement in 20 patients, with four of these patients recording the lowest possible score. There was a 29.5 point improvement in mean metric MOXFQ Index score. Seventy-nine percent (n = 19) of patients were satisfied or very satisfied with the operated foot. The average recoil of the metatarsal heads following DMMO was M2 4.01 mm, M3 4.55 mm, M4 4.16 mm. There was one delayed union and no non-unions. Further reported complications were a gastric bleed, pulmonary embolism (VTE), and one intra operative broken burr. CONCLUSION Our study demonstrates a clinically important and statistically significant improvement in patient reported outcomes following DMMO, with 79% of patients satisfied or very satisfied with this procedure. The average recoil of the metatarsal heads following DMMO was M2 4.01 mm, M3 4.55 mm, M4 4.16 mm with one delayed union and no non-unions.
Collapse
Affiliation(s)
| | | | - M Ellis
- Queen Margaret University, Musselburgh, United Kingdom
| | | | - G Baer
- Queen Margaret University, Musselburgh, United Kingdom
| | | | | |
Collapse
|
13
|
Gillette M, Krug K, Satpathy S, Jaehnig E, Karpova A, Clauser K, Tang L, Blumenberg L, Kothadia R, Ruggles K, Zhang B, Ding L, Mertins P, Mani DR, Ellis M, Carr S. Abstract TS1-2: Proteogenomic Landscape of Prospectively Collected Breast Cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-ts1-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A persistent central deficiency in our knowledge of cancer concerns how genomic changes drive the proteome and phosphoproteome to execute phenotypic characteristics. Furthermore increasing evidence implicating epigenetic and post-translational changes in cancer biology reinforce the notion that molecular profiles based on nucleic acids are incomplete and are critically complemented by analyses of proteins and their post-translational modifications. We present the first integrated proteogenomic study on a prospectively collected breast cancer cohort, and provide new insights including on taxonomy, metabolic dependencies, and immune milieu. 122 invasive ductal breast cancer samples were collected under the auspices of the National Cancer Institute’s Clinical Proteomics Tumor Analysis Consortium using rigorous protocols to minimize ischemic time and other pre-analytical variability. Samples underwent comprehensive genomic and proteomic characterization, providing whole exome, whole genome, copy number, RNAseq, global proteome, phosphoproteome, and acetylome data. Multi-omics clustering by nonnegative matrix factorization revealed basal-, luminal A-, and HER2-enriched clusters, as well as a combined luminal A/B cluster. Luminal A and A/B clusters were distinguished by differential expression of cytoskeletal signatures possibly driven by YAP1 overexpression and hyper-phosphorylation in the luminal A subset. Kinase outlier analysis revealed luminal A enrichment of PEAK1, an atypical kinase that regulates YAP1 expression. PTPN2, recently shown to synergize with anti-PD1 therapy, was an outlier in basal tumors, suggesting therapeutic opportunities in that difficult-to-treat subtype. Acetylation plays a dominant role in mitochondrial metabolism, and downregulation of deacetylase SIRT3 in basal and HER2-enriched samples was associated with upregulation of TCA cycle- and amino acid metabolism-related proteins suggesting metabolic dependencies that could be exploited. Immunological subtyping of the breast cohort identified immune-cold, immune-hot, immune-excluded and interferon-independent clusters associated with distinct patterns of tumor-infiltrating lymphocytes. Basal tumors generally overexpressed PDL1 relative to other subtypes, whereas the newly described immuno-oncology target SIGLEC15 was overexpressed in luminal tumors. While these and other analyses are intended to provide new insights into breast cancer biology and facilitate testable therapeutic hypotheses, the larger purpose of the program is to provide a resource to the breast cancer and broader scientific communities. To facilitate this, these and previously published data will be integrated to provide a sample set of 199 proteogenomically characterized breast cancers for further exploration.
Citation Format: M Gillette, K Krug, S Satpathy, E Jaehnig, A Karpova, K Clauser, L Tang, L Blumenberg, R Kothadia, K Ruggles, B Zhang, L Ding, P Mertins, DR Mani, M Ellis, S Carr. Proteogenomic Landscape of Prospectively Collected Breast Cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr TS1-2.
Collapse
Affiliation(s)
- M Gillette
- 1Broad Institute of MIT and Harvard, Massachusetts General Hospital, Cambridge, MA
| | - K Krug
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | - S Satpathy
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | - E Jaehnig
- 3Baylor College of Medicine, Houston, TX
| | - A Karpova
- 4Washington University School of Medicine, St. Louis, MO
| | - K Clauser
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | - L Tang
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | | | - R Kothadia
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | | | - B Zhang
- 3Baylor College of Medicine, Houston, TX
| | - L Ding
- 4Washington University School of Medicine, St. Louis, MO
| | | | - DR Mani
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| | - M Ellis
- 3Baylor College of Medicine, Houston, TX
| | - S Carr
- 2Broad Institute of MIT and Harvard, Cambridge, MA
| |
Collapse
|
14
|
Sparano J, Gray R, Makower D, Albain K, Saphner T, Badve S, Wagner L, Mihalcioiu C, Desbiens C, Hayes D, Dees E, Geyer C, Olson J, Wood W, Lively T, Paik S, Ellis M, Abrams J, Sledge G. Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Scaglioni D, Catapano F, Ellis M, Torelli S, Chambers D, Feng L, Frank D, Nair A, Harriman S, Dugar A, Morgan J, Phadke R, Muntoni F. P.146Novel high-throughput digital analysis to quantify the amount of functional sarcolemmal dystrophin and myofibre regeneration in Duchenne muscular dystrophy clinical trial samples (exon 53 skipping with golodirsen). Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Ripperger D, Ellis M, Triplett R. Oral and Maxillofacial Surgery Resident-Placed Dental Implants Show Increased Survival Compared to Faculty at a U.S. Dental College. J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.joms.2019.06.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Taliercio V, Langner A, Ellis M, Secrest A, Duffin K. 600 Assessing psoriasis severity: Clinimetric validation of overall physician global assessment. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
18
|
Niravath P, Wang T, Hilsenbeck SG, Lipscomb K, Pavlick A, Jiralerspong S, Nangia J, Ellis M, Ademuyiwa F, Cherian M, Frith A, Ma C, Park H, Rigden C, Suresh R, Osborne CK, Rimawi MF. Abstract PD6-02: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd6-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approximately half of women on aromatase inihbitor (AI) therapy develop AI-induced arthralgia (AIA), and many discontinue the medication because of this common side effect. While Vitamin D has been studied as a treatment for AIA, trial results have been conflicting thus far.
Patients and Methods: All subjects were post menopausal women who were beginning adjuvant AI therapy for stage I-III hormone receptor positive breast cancer. Patients were randomized 1:1 to receive standard dose vitamin D3 (800 IU daily for 52 weeks) or high dose vitamin D3 (50,000 IU weekly for 12 weeks, followed by 2000 IU daily for 40 weeks). All patients also took oral calcium 600 mg daily. The primary endpoint was development of AIA, as defined by pre-specified changes in the Health Assessment Questionnaire II (HAQ-II). Secondary endpoints include compliance with AI therapy, and correlation between grip strength and development of AIA. Exploratory endpoint was measurement of inflammatory cytokine reduction in each arm. The trial was designed to enroll 184 patients, but this futility analysis was performed after 93 patients were enrolled. The futility boundary for stopping the trial early was calculated as p = 0.47.
Results: All 93 patients (46 in the high dose arm, and 47 in the standard dose arm) enrolled in the study at the time of the interim analysis were evaluable. The HAQ-II was completed at 12 weeks in 76% on the high dose arm, and 68% in the standard dose arm. Subjects who did not complete the questionnaire were deemed as study failures (i.e. development of AIA was assumed). In the high dose arm, 25 patients (54%) developed AIA, compared to 27 patients (57%) in the standard dose arm. The one-tailed p value is 0.3818, and the Z-score is 0.3, yielding only a 38% conditional power that that study would find a significant difference between the two arms. Thus, the study was terminated early for futility. There was no significant difference between the two arms in adherence to AI therapy. The grip strength and inflammatory cytokine data are pending at this time. They will be ready by the time of the conference.
Conclusions: There was no significant signal for benefit of high dose vitamin D supplementation, as compared to standard dose vitamin D, for AIA prevention in post menopausal women taking adjuvant AI therapy. These results further characterize the role of Vitamin D in AIA, and they inform future clinical trials in this arena. Further research is necessary, as this remains an important cause of non-adherence to this highly effective therapy.
Citation Format: Niravath P, Wang T, Hilsenbeck SG, Lipscomb K, Pavlick A, Jiralerspong S, Nangia J, Ellis M, Ademuyiwa F, Cherian M, Frith A, Ma C, Park H, Rigden C, Suresh R, Osborne CK, Rimawi MF. A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD6-02.
Collapse
Affiliation(s)
- P Niravath
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - T Wang
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - SG Hilsenbeck
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - K Lipscomb
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - A Pavlick
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - S Jiralerspong
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - J Nangia
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - M Ellis
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - F Ademuyiwa
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - M Cherian
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - A Frith
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - H Park
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - C Rigden
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - R Suresh
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - CK Osborne
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| | - MF Rimawi
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
19
|
Shulman M, Cuthbertson B, Wijeysundera D, Pearse R, Thompson B, Torres E, Ambosta A, Wallace S, Farrington C, Myles P, Wallace S, Thompson B, Ellis M, Borg B, Kerridge R, Douglas J, Brannan J, Pretto J, Godsall M, Beauchamp N, Allen S, Kennedy A, Wright E, Malherbe J, Ismail H, Riedel B, Melville A, Sivakumar H, Murmane A, Kenchington K, Gurunathan U, Stonell C, Brunello K, Steele K, Tronstad O, Masel P, Dent A, Smith E, Bodger A, Abolfathi M, Sivalingam P, Hall A, Painter T, Macklin S, Elliott A, Carrera A, Terblanche N, Pitt S, Samuels J, Wilde C, MacCormick A, Leslie K, Bramley D, Southcott A, Grant J, Taylor H, Bates S, Towns M, Tippett A, Marshall F, McCartney C, Choi S, Somascanthan P, Flores K, Beattie W, Karkouti K, Clarke H, Jerath A, McCluskey S, Wasowicz M, Granton J, Day L, Pazmino-Canizares J, Hagen K, Campbell D, Short T, Van Der Westhuizen J, Higgie K, Lindsay H, Jang R, Wong C, Mcallister D, Ali M, Kumar J, Waymouth E, Kim C, Dimech J, Lorimer M, Tai J, Miller R, Sara R, Collingwood A, Olliff S, Gabriel S, Houston H, Dalley P, Hurford S, Hunt A, Andrews L, Navarra L, Jason-Smith A, Thompson H, McMillan N, Back G, Melo M, Mamdani M, Hillis G, Wijeysundera H. Using the 6-minute walk test to predict disability-free survival after major surgery. Br J Anaesth 2019; 122:111-119. [DOI: 10.1016/j.bja.2018.08.016] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 08/13/2018] [Accepted: 08/29/2018] [Indexed: 11/16/2022] Open
|
20
|
Perrott M, Cook J, Ellis M, Pizzari T. Movement variability improved more with stability exercise than stretching: A randomised controlled trial. J Sci Med Sport 2018. [DOI: 10.1016/j.jsams.2018.09.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Ellis M, Sardone V, Torelli S, Saeed S, Sigurta A, Hill N, Scaglioni D, Feng L, Sewry C, Singer M, Muntoni F, Phadke R. NEXT GENERATION SEQUENCING AND EXPERIMENTAL MYOLOGY. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Bikdeli B, Lobo JL, Jimenez D, Green P, Fernandez-Capitan C, Bura-Riviere A, Otero R, Ditullio M, Galindo S, Ellis M, Parikh S, Monreal M. P1627Early use of echocardiography in patients with acute pulmonary embolism: findings from the RIETE registry. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- B Bikdeli
- Columbia University Medical Center, Division of Cardiology; Center for Outcomes Research and Evaluation, Yale School of Medicine; CRF, New York, United States of America
| | - J L Lobo
- University Hospital of Araba, Alava, Spain
| | - D Jimenez
- University Hospital Ramon y Cajal de Madrid, Madrid, Spain
| | - P Green
- Columbia University Medical Center, New York, United States of America
| | | | - A Bura-Riviere
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - R Otero
- University Hospital of Virgen del Rocio, Seville, Spain
| | - M Ditullio
- Columbia University Medical Center, New York, United States of America
| | - S Galindo
- S&H Medical Sciences Services, Madrid, Spain
| | - M Ellis
- Meir Medical Center, Kfar Saba, Israel
| | - S Parikh
- Columbia University Medical Center, New York, United States of America
| | - M Monreal
- Germans Trias i Pujol Hospital, Badalona (Barcelona), Spain
| |
Collapse
|
23
|
Stasko K, Close S, King B, Geary J, Garrity H, Schott D, Bagley J, Crown D, Ellis M, Sturtevant O, Emmert A, Ritz J, Nikiforow S. How optimizing efficiency for autologous stem cell collection can set the stage for novel cell therapy growth in multiple departments. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
24
|
Cooper NC, Ellis M, Xiong Y, Gates R. 4 Effect of Piglet Birth Weight on Post-Natal Changes in Body Temperature. J Anim Sci 2018. [DOI: 10.1093/jas/sky073.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- N C Cooper
- University of Illinois, Urbana-Champaign, IL
| | - M Ellis
- University of Illinois, Urbana-Champaign, IL
| | - Y Xiong
- University of Illinois.edu, Champaign-Urbana, IL
| | - R Gates
- University of Illinois, Champaign-Urbana, IL
| |
Collapse
|
25
|
Harper HM, Vande Pol KD, Laudwig AL, Ellis M, Gaines AM, Peterson BA, Shull CM. 6 Evaluation of the Effect of Farrowing Pen Width on Piglet Pre-Weaning Mortality. J Anim Sci 2018. [DOI: 10.1093/jas/sky073.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H M Harper
- University of Illinois, Urbana-Champaign, IL
| | | | | | - M Ellis
- University of Illinois, Urbana-Champaign, IL
| | | | | | | |
Collapse
|
26
|
Schmitt RL, Ellis M, Mendoza OF, Shull CM, McKilligan D, Upah N. 216 The Effect of Administration of a Nutrient Dense Liquid at Weaning on Growth Performance and Morbidity and Mortality of Pigs during the Nursery Period Under Commercial Conditions. J Anim Sci 2018. [DOI: 10.1093/jas/sky073.213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- R L Schmitt
- University of Illinois, Urbana-Champaign, IL
| | - M Ellis
- University of Illinois, Urbana-Champaign, IL
| | | | | | | | - N Upah
- TechMix Global, Stewart, MN
| |
Collapse
|
27
|
Vande Pol KD, Ellis M, Laudwig AL, Gaines AM, Peterson BA, Shull CM. 19 Effect of Gestation Housing System (Individual vs. Group) on the Reproductive Performance of Sows over 6 Parities Under Commercial Conditions. J Anim Sci 2018. [DOI: 10.1093/jas/sky073.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - M Ellis
- University of Illinois, Urbana-Champaign, IL
| | | | | | | | | |
Collapse
|
28
|
Sanati S, Barve R, Luo J, Hoog J, Head R, Ellis M, Ma C. Abstract P2-09-16: Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors improve disease free survival for patients (pts) with advanced hormone receptor positive (HR+) and HER2 negative (HER2-) breast cancer (BC). However, there are no established biomarkers that identify sensitive versus resistant tumors. We have recently reported results from the phase II neoadjuvant NeoPalAna trial (NCT01723774 ) which demonstrated that Pal enhanced the anti-proliferative activity when added to anastrozole (Ana) monotherapy in HR+HER2- BC. Interestingly, a small group of pts (15%) were resistant to Pal, exhibiting persistent tumor cell proliferation (Ki67 >2.7%) on Ana plus Pal. Several studies have evaluated the prognostic and predictive importance of TILs in BC, particularly in triple negative and HER2+ subtypes. Studies evaluating TILs in HR+ BC is limited. Here we evaluated the utility of TILs in identifying Pal-resistant tumors.
Methods: Serial biopsies were collected from pts at 4 time points: baseline (BL), cycle 1 day 1 (C1D1) following 28 days of Ana monotherapy, cycle 1 day 15 (C1D15) at 2 weeks post the addition of Pal, and at surgery (Surg). TILs were evaluated using published recommendations by the TILs international working group. Agilent 4X44 whole genome gene expression arrays performed on fresh frozen biopsies at BL, C1D1, and C1D15 were analyzed for pathways and gene signatures that differentiate Pal-resistant (Pal-r) (C1D15 Ki67 >2.7%) from Ana-sensitive (Ana-s) (C1D1 Ki67 ≤2.7%) or Pal- sensitive (Pal-s) (C1D1 Ki67 >2.7% but C1D15 Ki67 ≤2.7%) tumors defined by Ki67 response. TILs at each time point were pairwise compared between response groups using Wilcoxon rank sum test and Benjamini-Hochberg adjusted two-sided p-values were reported. Change between 2 time points within a response group was evaluated by Wilcoxon signed rank test.
Results: The TILs were significantly different between Ana-s and Pal-s groups [BL p=0.03, C1D1 p=0.01, C1D15 p=.02], as well as between Ana-s and Pal-r groups [BL p=0.03, C1D1 p=0.04, C1D15 p=0.02]. Overall Pal-r samples showed the highest TILs at all time points, while Ana-s samples showed the lowest TILs. There was no significant change between time points.
Elevated TILs in Pal-r group was further supported by microarray gene expression analysis which demonstrated a large group of genes associated MHC Class-I (15+ HLA and proteasome genes) as well as Immune–inflammation pathways (18+ T cell & lymphocyte markers, signaling genes) being up regulated at BL in the Pal-r group (n=5). Pal-r samples showed a similar trend in subsequent time points although the numbers of samples were small. Many genes within this immune-inflammatory group of genes were correlated with Ki67 change at C1D15 from BL, suggestive of a potential relationship with resistance.
Conclusions: Our data shows Pal resistance was consistently associated with higher TILs at BL and post treatment, which correlated with increased expression of inflammation-immune group genes. TILs may have utility to be used as a biomarker to identify Pal resistant BC. Our data is hypothesis generating and raises the possibility of immune therapy to overcome Pal resistance in BC.
Citation Format: Sanati S, Barve R, Luo J, Hoog J, Head R, Ellis M, Ma C. Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-16.
Collapse
Affiliation(s)
- S Sanati
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - R Barve
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - J Luo
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - J Hoog
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - R Head
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - M Ellis
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| | - C Ma
- Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX
| |
Collapse
|
29
|
Chang EC, Zheng Z, Philip L, Burcu C, Lei J, Singh P, Anurag M, Chan D, Li JD, Du XP, Shafaee MN, Banks K, Sacker S, Song W, Nguyen T, Cao J, Chen X, Haricharan S, Kavuri M, Kim BJ, Zhang B, Gutmann DH, Lanman RB, Foulds C, Ellis M. Abstract GS2-02: Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs2-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Inactivating germline mutations in the NF1 gene (encoding neurofibromin) cause neurofibromatosis type 1. In addition to peripheral nervous system tumors, NF1 patients are at higher risk for other cancers, including breast cancer. Tumor exome-sequencing studies demonstrate that approximately 20% of all human cancers have somatic NF1 mutations. NF1 has been best known for its ability to inactivate Ras as a GAP (GTPase Activating Protein). However, this function is served by a small GAP domain in a very large protein. Recurrent missense mutations inactivating the GAP activity are infrequent. In contrast, it is common to detect frameshift (FS) and nonsense (NS) NF1 mutations, which can create an NF1-null state deleting not only GAP, but also, potentially, undefined NF1 functions whose loss could also drive tumorigenesis.
As we reported at SABCS previously, in 600+ patients treated by tamoxifen adjuvant monotherapy, we found that FS/NS NF1 mutations independently correlate with relapse risk (HR=2.6, p=0.03). To explore this finding, we silenced NF1 in preclinical models of ER+ breast cancer, which markedly enhanced ER transcriptional activities, causing estradiol (E2) hypersensitivity and converted tamoxifen into an agonist (in vitro and in vivo). Most important, these activities depend on ER, but not on NF1's GAP activity. These findings readily explain the poor patient outcomes associated with NS/FS NF1 mutations, and reveal a previously unrecognized function for NF1 in ER regulation.
In the presence of an agonist, liganded ER repels co-repressors and recruits co-activators, while the reverse is true with an antagonist such as tamoxifen. Many co-regulators contain leucine/isoleucine rich motifs, which bind directly to the ligand-binding domain (LBD) in ER. NF1 has several of these motifs that are much more highly conserved in species with a functional ER pathway, and some of these are mutated in cancers (e.g., in our patient cohort). Furthermore, we found that NF1 canbind directly to ER, and that this binding is mediated between the ER LBD and the NF1 leucine-rich regions. Like a classic co-repressor, wildtype NF1 (but not mutants lacking GAP activity or the Leu-rich motif) binds to ER, and is recruited by ER to the ERE in the presence of tamoxifen, but not E2.
Further preclinical treatment studies indicate that while NF1-deficient ER+ breast cancer should not be treated by tamoxifen or AIs, fulvestrant remains effective. Furthermore, when fulvestrant is combined with dabrafinib and trametinib to inhibit Ras effectors Raf and MEK, apoptosis is induced in vitro, and tumor regression is observed in vivo. In conclusion, we have demonstrated that NF1 is a dual negative regulator at the intersection of two potent oncogenic signaling pathways, Ras and ER, and that NF1-deficient ER+ breast cancer patients may be more effectively treated by co-targeting the Ras and ER signaling. These patients, up to 10% of those with advanced ER+ breast cancer, can be readily identified for treatment by ctDNA analysis. A clinical trial is under development.
Citation Format: Chang EC, Zheng Z, Philip L, Burcu C, Lei J, Singh P, Anurag M, Chan D, Li JD, Du XP, Shafaee MN, Banks K, Sacker S, Song W, Nguyen T, Cao J, Chen X, Haricharan S, Kavuri M, Kim B-J, Zhang B, Gutmann DH, Lanman RB, Foulds C, Ellis M. Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS2-02.
Collapse
Affiliation(s)
- EC Chang
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - Z Zheng
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - L Philip
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - C Burcu
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - J Lei
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - P Singh
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - D Chan
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - JD Li
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - XP Du
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - MN Shafaee
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - K Banks
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - S Sacker
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - W Song
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - T Nguyen
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - J Cao
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - X Chen
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Kavuri
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - B-J Kim
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - B Zhang
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - DH Gutmann
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - RB Lanman
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - C Foulds
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Ellis
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| |
Collapse
|
30
|
Raymond VM, Diaz J, Banks KC, Ahn E, Brufsky A, Ellis M, Lippman M, Lee C, Pluard T, Schreeder M, Schwab R, Lanman RB. Abstract P2-02-12: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Identification of ERBB2 (HER2) overexpression in metastatic breast cancer informs utilization of HER2 targeted therapy. The NCCN recommends HER2 expression re-evaluation at the first disease recurrence in patients with negative or equivocal tissue status given results discrepancies due to inadequate tissue biopsy, tumoral heterogeneity, biopsy technique or fixation as well as discordance in ERBB2 (HER2) expression between primary and metastatic lesions. We examined the incidence of ERBB2 (HER2) negative to positive “flips” (e.g. to ERBB2-amplified in plasma) in a cohort of patients who underwent a blood-based cell-free DNA (cfDNA) assay at a CLIA-certified/CAP-accredited/NYSDOH-approved molecular diagnostic laboratory.
Laboratory database was queried for samples from patients with a breast cancer diagnosis. The query was filtered to ensure patients with multiple cfDNA timepoints were counted only once. Patients without a pathology report submitted at any cfDNA collection timepoint or the pathology report did not include ERBB2 (HER2) status, results were inconclusive or quantity not sufficient were excluded. Between March 2014 and April 2017, 1,853 unique patients were identified with reported ERBB2 (HER2) status. For patients with more than one cfDNA timepoint collected (N=349; 18.8%), the earliest pathology report was referenced. 1,386 patient tumor samples were negative for HER2 overexpression (74.8%), 325 (17.5%) were positive, and 142 (7.7%) were equivocal. Twenty-nine of the 1,386 patients with reported tumor negative HER2 status had amplification on subsequent cfDNA analysis (2.1%).
All 29 patients were female. Most patients (N=21) had a single cfDNA timepoint collected. Median age at cfDNA blood draw was 58 years (range 28–68). Median length of time between reported tissue negative status and cfDNA blood draw was 405 days (range 21–4,060). Median plasma ERBB2 copy number was 2.44 (greater than 50th-centile per laboratory data) (range 2.15–16.5).
Clinical follow-up was obtained for 19 patients (65%). Nine patients were lost to follow-up or succumbed to disease prior to initiation of a new therapeutic regimen. One patient was known HER2 positive prior to receipt of the cfDNA results. In the remaining nine patients, six initiated targeted HER2 therapy following receipt of the cfDNA results, with five of six (83%) demonstrating a clinical response. In one patient with known ER/PR positive, HER2 negative disease, progressing through multiple lines of therapy, addition of trastuzumab and pertuzumab to her paclitaxel regimen following identification of the cfDNA ERBB2 amplification resulted in a significant reduction in CEA levels (238 to 37.9 ng/mL) by week five. In a second patient, following identification of the cfDNA ERBB2 amplification, she was treated with trastuzumab and pertuzumab along with docetaxel and had a dramatic response. She continues on trastuzumab and pertuzumab alone.
Although a modest sample size, this is the second cfDNA series demonstrating that ERBB2 (HER2) status may flip from negative to positive upon recurrence or metastasis, and that targeting plasma-detected ERBB2 amplification with anti-HER2 has clinical benefit. cfDNA is a viable alternative to tissue rebiopsy in this patient population.
Citation Format: Raymond VM, Diaz J, Banks KC, Ahn E, Brufsky A, Ellis M, Lippman M, Lee C, Pluard T, Schreeder M, Schwab R, Lanman RB. Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-12.
Collapse
Affiliation(s)
- VM Raymond
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - J Diaz
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - KC Banks
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - E Ahn
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - A Brufsky
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - M Ellis
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - M Lippman
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - C Lee
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - T Pluard
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - M Schreeder
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - R Schwab
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| | - RB Lanman
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Zion, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine, Miami, FL; St. Luke's Health System, Kansas City, MO; Clear View Cancer Center, Huntsville, AL; University of California, San Diego, San Diego, CA
| |
Collapse
|
31
|
Ritter MJ, Johnson AK, Benjamin ME, Carr SN, Ellis M, Faucitano L, Grandin T, Salak-Johnson JL, Thomson DU, Goldhawk C, Calvo-Lorenzo MS. Review: Effects of Ractopamine Hydrochloride (Paylean) on welfare indicators for market weight pigs. Transl Anim Sci 2017; 1:533-558. [PMID: 32704677 PMCID: PMC7204987 DOI: 10.2527/tas2017.0060] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 10/20/2017] [Indexed: 11/13/2022] Open
Abstract
This review summarizes the effects of ractopamine hydrochloride (RAC) dose (5, 7.5, 10, and 20 mg/kg) on market weight pig welfare indicators. Ractopamine hydrochloride (trade name Paylean) is a β-adrenergic agonist that was initially approved in the U.S. in 1999 at doses of 5 to 20 mg/kg to improve feed efficiency and carcass leanness. However, anecdotal reports suggested that RAC increased the rate of non-ambulatory (fatigued and injured) pigs at U.S. packing plants. This led to the addition of a caution statement to the Paylean label, and a series of research studies investigating the effects of RAC on pig welfare. Early research indicated that: (1) regardless of RAC administration, fatigued (non-ambulatory, non-injured) pigs are in a state of metabolic acidosis; (2) aggressive handling increases stress responsiveness at 20 mg/kg RAC, while 5 mg/kg reduces stress responsiveness to aggressive handling. Given this information, dosage range for Paylean was changed in 2006 to 5 to 10 mg/kg in market weight pigs. Subsequent research on RAC demonstrated that: (1) RAC has minimal effects on mortality, lameness, and home pen behavior; (2) RAC fed pigs demonstrated inconsistent prevalence and intensity of aggressive behaviors; (3) RAC fed pigs may be more difficult to handle at doses above 5 mg/kg; and (4) RAC fed pigs may have increased stress responsiveness and higher rates of non-ambulatory pigs when subjected to aggressive handling, especially when 20 mg/kg of RAC is fed.
Collapse
Affiliation(s)
- M J Ritter
- Elanco Animal Health, Division of Eli Lilly and Company, Greenfield, IN 46140
| | - A K Johnson
- Department of Animal Science, Iowa State University, Ames, 50011
| | - M E Benjamin
- College of Veterinary Medicine, Michigan State University, East Lansing, 48824
| | - S N Carr
- Elanco Animal Health, Division of Eli Lilly and Company, Greenfield, IN 46140
| | - M Ellis
- Department of Animal Sciences, University of Illinois, Champaign, 61801
| | - L Faucitano
- Agriculture and Agri-Food Canada, Sherbrooke Research and Development Centre, Sherbrooke, Quebec J1M 0C8
| | - T Grandin
- Department of Animal Sciences, Colorado State University, Fort Collins, 80523
| | - J L Salak-Johnson
- Department of Animal Sciences, University of Illinois, Champaign, 61801
| | - D U Thomson
- Department of Diagnostic Medicine and Pathobiology, Kansas State University, Manhattan, 66506
| | - C Goldhawk
- Elanco Animal Health, Division of Eli Lilly and Company, Greenfield, IN 46140
| | - M S Calvo-Lorenzo
- Elanco Animal Health, Division of Eli Lilly and Company, Greenfield, IN 46140
| |
Collapse
|
32
|
Ma J, Bell A, Setton J, Haseltine J, Thompson M, Shah R, Lok B, Delsite R, Ellis M, Aft R, Riaz N, Powell S. In Vitro Characterization and Clinical Correlation of BRCAness as a Personalized Biomarker for Radiosensitization With Homologous Recombination Directed Therapies. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.2059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Conte S, Pomar C, Paiano D, Duan Y, Zhang P, Lévesque J, Guay F, Ellis M, Devillers N, Faucitano L. 371 The effect of feeding a high-fiber and -fat diet on pig meat quality. J Anim Sci 2017. [DOI: 10.2527/asasann.2017.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Puls CL, Rojo A, Matzat PD, Schroeder AL, Ellis M. Behavior of immunologically castrated barrows in comparison to gilts, physically castrated barrows, and intact male pigs. J Anim Sci 2017; 95:2345-2353. [DOI: 10.2527/jas.2016.1335] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Wilson KB, Overholt MF, Hogan EK, Schwab C, Shull CM, Ellis M, Grohmann NS, Dilger AC, Boler DD. Predicting pork loin chop yield using carcass and loin characteristics. J Anim Sci 2017; 94:4903-4910. [PMID: 27898928 DOI: 10.2527/jas.2016-0610] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objective was to determine the predictive ability of carcass length for the number of equal-thickness chops obtained from a boneless pork loin. Longer pork carcasses are assumed to yield longer loins and, therefore, an increased number of chops. Loins were collected from pigs (1,238 total) raised under commercial conditions and marketed when the mean pig weight in a pen reached 138 kg. Pigs were slaughtered over 7 wk in a commercial facility. Carcass length was measured at 1 d postmortem on the left side of each carcass from the anterior edge of the symphysis pubis bone to the anterior edge of the first rib. Carcasses were fabricated, and boneless loins (North American Meat Processors number 414) were vacuum packaged and transported to the University of Illinois Meat Science Laboratory. Loins were stored at 4°C for 14 d. At the end of the aging period, loins were weighed, measured for stretched length (stretched to maximum length without distortion) and compressed length (compressed to minimum length without distortion), and sliced into 2.54-cm-thick chops. Boneless chops were counted and weighed. Carcass length ranged from a minimum of 78.2 cm to a maximum of 96.5 cm and the number of boneless chops ranged from a minimum of 13 to a maximum of 20 chops. Data were analyzed using the regression procedure of SAS. The dependent variable was the number of boneless chops. Coefficient of determination () was calculated for carcass length, boneless loin weight, compressed loin length, and stretched loin length. Carcass length explained 15% ( < 0.0001) of the variation in the number of loin chops. Loin weight explained 33% ( < 0.0001) of the variation in the number of loin chops. Compressed loin length and stretched loin length explained 28 and 8% ( < 0.0001), respectively, of the variation in the number of loin chops. Multiple linear regression was used to determine a predictive equation for the number of loin chops using the stepwise selection option of all independent variables. The combination of boneless loin weight, compressed loin length, 10th-rib carcass fat depth, and carcass length explained 45% of the variation ( < 0.0001; C(p) = 16.76) in the number of loin chops using a required statistic at the SLENTRY and SLSTAY level = 0.15. Overall, carcass length is a poor predictor of the number of equal-thickness loin chops that can be derived from a boneless pork loin.
Collapse
|
36
|
Alqahtani FF, Messina F, Kruger E, Gill H, Ellis M, Lang I, Broadley P, Offiah AC. Evaluation of a semi-automated software program for the identification of vertebral fractures in children. Clin Radiol 2017; 72:904.e11-904.e20. [PMID: 28506798 DOI: 10.1016/j.crad.2017.04.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 03/24/2017] [Accepted: 04/11/2017] [Indexed: 11/19/2022]
Abstract
AIM To assess observer reliability and diagnostic accuracy in children, of a semi-automated six-point technique developed for vertebral fracture (VF) diagnosis in adults, which records percentage loss of vertebral body height. MATERIALS AND METHODS Using a semi-automated software program, five observers independently assessed T4 to L4 from the lateral spine radiographs of 137 children and adolescents for VF. A previous consensus read by three paediatric radiologists using a simplified algorithm-based qualitative technique (i.e., no software involved) served as the reference standard. RESULTS Of a total of 1,781 vertebrae, 1,187 (67%) were adequately visualised according to three or more observers. Interobserver agreement in vertebral readability for each vertebral level for five observers ranged from 0.05 to 0.47 (95% CI: -0.19, 0.76). Intra-observer agreement using the intraclass correlation coefficient (ICC) ranged from 0.25 to 0.61. The overall sensitivity and specificity were 18% (95% CI: 14-22) and 97% (95% CI: 97-98), respectively. CONCLUSION In contrast to adults, the six-point technique assessing anterior, middle, and posterior vertebral height ratios is neither satisfactorily reliable nor sensitive for VF diagnosis in children. Training of the software on paediatric images is required in order to develop a paediatric standard that incorporates not only specific vertebral body height ratios but also the age-related physiological changes in vertebral shape that occur throughout childhood.
Collapse
Affiliation(s)
- F F Alqahtani
- Academic Unit of Child Health, University of Sheffield, Sheffield, UK; Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia.
| | - F Messina
- School of Health and Related Research, University of Sheffield, Sheffield, UK
| | - E Kruger
- Radiology Department, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - H Gill
- Sheffield Medical School, University of Sheffield, Sheffield, UK
| | - M Ellis
- Sheffield Medical School, University of Sheffield, Sheffield, UK
| | - I Lang
- Radiology Department, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - P Broadley
- Radiology Department, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - A C Offiah
- Academic Unit of Child Health, University of Sheffield, Sheffield, UK; Radiology Department, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| |
Collapse
|
37
|
Morris JR, Ellis M, Estrada JE, Gaines AM, Shull CM, Mendoza OF. 214 Effects of a liquid supplement and a nursery starter diet given immediately post-weaning on growth performance and morbidity and mortality of nursery pigs. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.12.214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Pol KDV, Ellis M, Shull CM, Gaines AM, Mendoza OF, Parr E. 216 Effect of a post-weaning supplemental nutrition program on the growth performance, and morbidity and mortality of nursery pigs. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.12.216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Grohmann NS, Ellis M, Nankivil JJ, Cooper NC, Shull CM, Peterson BA, Gaines AM. 130 Effects of antibiotic program and floor space in the nursery and grow-finish periods on wean-to-finish growth performance of pigs under commercial conditions. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Estrada JE, Ellis M, Stas NM, Cooper NC, Gaines AM, Shull CM, Mendoza OF. 268 Effect of number of dietary phases fed during the wean-to-finish period on growth performance and carcass characteristics of pigs under commercial conditions. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Stas NM, Ellis M, Grohmann NS, Schwab CR, Shull CM, Ewing K. 030 Effect of swine sire line and selection index category on wean-to-finish growth performance and carcass characteristics. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Estrada JE, Ellis M, Mendoza OF, Gaines AM. 195 Estimation of the productive energy content of corn germ meal based on a growth assay in wean-to-finish pigs. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.12.195] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Sardone V, Jones A, Ellis M, Torelli S, Feng L, Chambers D, Phadke R, Sewry C, Morgan J, Muntoni F. A semi-automated image processing method for quantify dystrophin coverage at the sarcolemma membrane of each individual muscle fibre. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30259-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Schmitt RL, Ellis M, Estrada JE, Gaines AM, Mendoza OF, Shull CM, Crowder SA, Karnezos TP. 177 The effect of feeding AmbitineFA on growth performance and carcass characteristics of finishing pigs. J Anim Sci 2017. [DOI: 10.2527/asasmw.2017.12.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Chai-Adisaksopha C, Alexander PE, Guyatt G, Crowther MA, Heddle NM, Devereaux PJ, Ellis M, Roxby D, Sessler DI, Eikelboom JW. Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. Vox Sang 2017; 112:268-278. [PMID: 28220494 DOI: 10.1111/vox.12495] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 01/03/2017] [Accepted: 01/06/2017] [Indexed: 01/28/2023]
Abstract
BACKGROUND Among transfused patients, the effect of the duration of red blood cell storage on mortality remains unclear. This study aims to compare the mortality of patients who were transfused with fresher versus older red blood cells. METHODS We performed an updated systematic search in the CENTRAL, MEDLINE, EMBASE and CINAHL databases, from January 2015 to October 2016. RCTs of hospitalized patients of any age comparing transfusion of fresher versus older red blood cells were eligible. We used a random-effects model to calculate pooled risk ratios (RRs) with corresponding 95% confidence interval (CI). RESULTS We identified 14 randomized trials that enrolled 26 374 participants. All-cause mortality occurred in 1219 of 9531 (12·8%) patients who received a transfusion of fresher red blood cells and 1810 of 16 843 (10·7%) in those who received older red blood cells (RR: 1·04, 95% CI: 0·98-1·12, P = 0·90, I2 = 0%, high certainty for ruling out benefit of fresh blood, moderate certainty for ruling out harm of fresh blood). In six studies, in-hospital death occurred in 691 of 7479 (9·2%) patients receiving fresher red cells and 1291 of 14 757 (8·8%) receiving older red cells (RR: 1·06, 95% CI: 0·97-1·15, P = 0·81, I2 = 0%, high certainty for ruling out benefit of fresh blood, moderate certainty for ruling out harm of fresh blood). CONCLUSION Transfusion of fresher red blood cells does not reduce overall or in-hospital mortality when compared with older red blood cells. Our results support the practice of transfusing patients with the oldest red blood cells available in the blood bank.
Collapse
Affiliation(s)
- C Chai-Adisaksopha
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
| | - P E Alexander
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
| | - G Guyatt
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
| | - M A Crowther
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.,Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - N M Heddle
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.,Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.,McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada.,Centre for Innovation Canadian Blood Services, Hamilton, ON, Canada
| | - P J Devereaux
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.,Population Health Research Institute, Hamilton, ON, Canada
| | - M Ellis
- Meir Medical Centre Kfar Saba and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Roxby
- SA Pathology Transfusion Service, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia
| | - D I Sessler
- Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA
| | - J W Eikelboom
- Department of Medicine, McMaster University, Hamilton, ON, Canada.,Population Health Research Institute, Hamilton, ON, Canada.,Thrombosis & Atherosclerosis Research Institute, Hamilton, ON, Canada
| |
Collapse
|
46
|
Liu N, Thomas S, Luo R, Hoog J, Suh EM, Bergqvist M, Neumüller M, Guo Z, Vij K, Sanati S, Ellis M, Ma C. Abstract P5-04-02: Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Thymidine kinase 1 (TK1) is a fundamental enzyme in DNA synthesis. TK1 expression is E2F-dependent and peaks in the S-phase of the cell cycle. In preclinical studies, inhibition of cyclin-dependent kinase (CDK) 4/6 led to dose dependent reduction of TK1 activity in cultured media. We hypothesized that serum TK1 could serve as a non-invasive surrogate marker of cell proliferation in patients (pts) receiving CDK4/6 inhibitors. In this study, we examined serum TK1 activity from breast cancer (BC) pts enrolled on a neoadjuvant study of palbociclib (Palbo) plus anastrozole (A), for changes induced by Palbo, and correlated with changes in tumor Ki67.
Methods: In this phase II neoadjuvant study, 50 pts with clinical stage II or III estrogen receptor positive (ER+) HER2- BC, received A (in combination with goserelin if premenopausal) alone for 28 days in cycle 0 (C0), followed by the addition of Palbo (125 mg daily on days 1-21) on cycle 1 day 1 (C1D1) for 4 28-day cycles (C1 to C4) unless C1D15 tumor Ki67>10%, in which case pts went off study. Following completion of cycle 4, A was continued for another 3-5 weeks to allow Palbo washout prior to surgery, except in 8 pts who received an additional 10-12 days of Palbo immediately prior. Blood and tumor biopsies were collected at 4 time points: baseline, C1D1, C1D15, and surgery. Serum TK1 activity was measured using the highly sensitive Divitum™ assay according to the Divitum™ Instructions for use (Biovica, Sweden). Tumor Ki67 IHC was performed at the Washington University AMP laboratory using the CONFIRM anti-Ki67 rabbit monoclonal antibody (clone 30-9), and pathologist guided image analysis.
Results: There was no statistically significant difference in TK activity between baseline and C1D1 serum samples (Table 1). However, serum TK activity decreased significantly from C1D1 to C1D15 following the addition of Palbo and increased significantly from C1D15 to surgery following Palbo washout (Table 1), indicating a significant effect of Palbo on TK activity. At C1D15, TK activity was below the detection limit of 20 Du/L in 44 of 48 pts, and was at low levels (24, 26, 26, and 58 Du/L) in the remaining 4 pts, indicating a profound effect by Palbo. Interestingly, the TK activities of the 4 pts with tumor Ki67 >10% at C1D15 were all below 20 Du/L, suggesting the possibility of tumor cell proliferation independent of CDK4/6 inhibition.
The sensitivity and specificity of change (increase/decrease) in serum TK activity to predict tumor Ki67 (increase/decrease) induced by Palbo were 83% (19/23, 95%CI: 66-99%) and 93% (26/28, 95%CI: 83%-100%), respectively. The Kappa statistic was 0.761 (P<0.001), indicating substantial agreement between the two tests.
Conclusions: Serum TK1 activity may serve as a pharmacodynamics marker of CDK4/6 inhibition and further investigation is warranted.
Table 1. Serum TK1 and tumor Ki67 Serum TKKi67 Median (IQR) (Du/L)NMedian (IQR) (%)NBaseline46 (25-73)4824.34% (11.92%-35.43%)45Cycle 1 day 143 (27.5-98)495.37% (2.49%-13.59%)*45Cycle 1 day 1520 (20-20)*480.78% (0.23%-1.05%)*45Day of surgery136.0 (37.5-259)*378.33% (2.25%-23.03%)*34*P<0.001 compared to the preceding time point.
Citation Format: Liu N, Thomas S, Luo R, Hoog J, Suh EM, Bergqvist M, Neumüller M, Guo Z, Vij K, Sanati S, Ellis M, Ma C. Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-04-02.
Collapse
Affiliation(s)
- N Liu
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - S Thomas
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - R Luo
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - J Hoog
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - EM Suh
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - M Bergqvist
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - M Neumüller
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - Z Guo
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - K Vij
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - S Sanati
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - M Ellis
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| | - C Ma
- Washington University School of Medicine, St. Louis, MO; Biovica AB, Uppsala, Sweden; Baylor College of Medicine, Houston, TX
| |
Collapse
|
47
|
Cakar B, Chan D, Yan P, Zheng Z, Singh P, Lei JT, Haricharan S, Ellis M, Chang E. Abstract P1-08-07: Assessing the impact of loss of NF1 protein on endocrine therapy resistance. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The vast majority of breast cancers belong to the luminal subtype, which expresses the estrogen receptor-α (ER). Although great strides have been made in targeting the ER pathway for treating the ER+ tumors, relapse and death is common and ongoing. In order to identify the cause for treatment resistance, we have conducted a retrospective analyses on the tumor genomes of >600 patients treated by tamoxifen monotherapy in the adjuvant setting with a median follow-up of 10.4 years. Our data have revealed that NF1 (Neurofibromatosis type 1) gene loss of function mutations were greatly associated with poor prognosis. NF1 is a tumor suppressor acting mostly as a GAP (GTP ase activating protein) to switch off activated Ras. We aim to define the impact of loss of NF1 protein on patient outcome in ER+ breast cancer patients by establishing an immunohistochemistry (IHC) protocol to detect NF1.
Method and results: We have first surveyed commercially available antibodies by Western blot and found one that could efficiently detect endogenous NF1. We then use this to validate inducible shRNA clones against NF1, as well as a breast cancer cell line that is NF1-null. This antibody has high background. We have thus partially purified a commercially available NF1 antibody by preclearing using NF1-null cell lysate. We then performed immunostaining using NF1-silenced and null cells as control and found that NF1 is mostly cytoplasmic and nuclear. To get antibody of high quality, we have decided to make our own antibody by expressing a C-terminal fragment of NF1 as a GST-tagged protein (GST-NF1c). Production of polyclonal and monoclonal antibody is in progress.
Conclusion: Our clinical profiling data suggest that loss of NF1 protein, a very common event in a wide range of other cancers, promotes endocrine therapy resistance. An efficient IHC protocol will enable us to firmly validate whether loss of the NF1 protein indeed correlates with poor patient outcome. This method will ultimately enable us to identify high risk NF1 deficient patients and to properly treat them.
Citation Format: Cakar B, Chan D, Yan P, Zheng Z, Singh P, Lei JT, Haricharan S, Ellis M, Chang E. Assessing the impact of loss of NF1 protein on endocrine therapy resistance [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-08-07.
Collapse
Affiliation(s)
- B Cakar
- Baylor College of Medicine, Houston, TX
| | - D Chan
- Baylor College of Medicine, Houston, TX
| | - P Yan
- Baylor College of Medicine, Houston, TX
| | - Z Zheng
- Baylor College of Medicine, Houston, TX
| | - P Singh
- Baylor College of Medicine, Houston, TX
| | - JT Lei
- Baylor College of Medicine, Houston, TX
| | | | - M Ellis
- Baylor College of Medicine, Houston, TX
| | - E Chang
- Baylor College of Medicine, Houston, TX
| |
Collapse
|
48
|
Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Based on prospective clinical trials, there is no evidence for differences in efficacy between the 3 aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole. The purpose of this study was to identify germline genetic variants associated with response to AIs and to help identify novel mechanisms associated with drug disease efficacy.
METHODS: A genome-wide association study (GWAS) was performed for 624 patients (Steroids 2015;99:32-38) to identify SNPs associated with estrogen level change in women with estrogen receptor (ER) positive breast cancer treated with anastrozole. Replication of associated SNPs was performed in a GWAS from the MA.27 trial that compared adjuvant anastrozole and exemestane treatment of post-menopausal women with ER+ breast cancer. Functional studies were subsequently performed to determine SNP effects and underlying mechanisms.
RESULTS: Our initial GWAS identified SNPs within CSMD1 that were associated with changes in estrogen levels during anastrozole therapy. An additional SNP in CSMD1 was also associated with breast cancer events in CCTG MA.27. Functionally, we showed that CSMD1 regulates CYP19 expression in a SNP-, and in an anastrozole- dependent fashion. These phenomena were not observed for either letrozole or exemestane. In MA.27, an anastrozole- specific effect was also seen with the minor allele having a protective effect on time to distant metastasis (HR=0.49, p=0.00259), but this was not the case for exemestane (HR=0.71, p=0.111). Our in vitro functional studies indicated that overexpression of CSMD1 sensitized anastrozole or letrozole resistant cells to anastrozole but not to the other two AIs. The SNP in CSMD1 that was associated with increased CSMD1 and CYP19 expression levels increased anastrozole sensitivity, but not letrozole or exemestane in lymphoblastoid cell lines (LCLs) homozygous for either WT or variant CSMD1 SNP genotypes. Based on these observations, we explored whether anastrozole has additional mechanisms beyond its function as a CYP19 inhibitor. Utilizing an estrogen response element (ERE) luciferase reporter assay in a CYP19 CRISPR knockout breast cancer T47D cell line and a surface plasmon resonance (SPR) assay, we found that anastrozole can also function as an ERα agonist, and can bind to, and result in, proteasome dependent ERα degradation, especially in the presence of E2. Treatment of these CYP19 CRISPR knockout cells with anastrozole in the presence of increasing concentrations of E2 results in greater sensitivity compared with anastrozole alone, while the addition of E2, as expected, does not improve letrozole or exemestane sensitivity. These same observations were also seen in letrozole and anastrazole resistant cells.
CONCLUSIONS: Our findings suggest that anastrozole might be more effective than letrozole or exemestane in patients with the CSMD1 SNP. Furthermore, anastrozole can function as an ERα agonist, binding to ERα and resulting in its degradation, especially in the presence of E2. These findings should help to make it possible to develop precision endocrine therapies for women who are candidates for AIs.
Citation Format: Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-04.
Collapse
Affiliation(s)
- J Cairns
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - J Ingle
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - T Dudenkov
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - K Kalari
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - A Buzdar
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Kubo
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Robson
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Ellis
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - P Goss
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Shepherd
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Goetz
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Wang
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| |
Collapse
|
49
|
Corless D, Ellis M, Dawson E, Fraser F, Evans S, Perry JD, Silver CP, Reisner C, Beer M, Boucher BJ, Cohen RD. Using Activities of Daily Living Assessments to Measure the Effectiveness of Vitamin D Supplements in Elderly Long-Stay Patients. Br J Occup Ther 2016. [DOI: 10.1177/030802268705000208] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Selected activities of daily living were used to measure improvement in independence of long-stay elderly patients known to have low concentrations of plasma 25-hydroxyvitamin D. This was a double-blind random controlled trial lasting between 8 and 40 weeks. No significant changes were found in either group.
Collapse
Affiliation(s)
- D Corless
- Consultant Geriatrician, Guy's Hospital, London
| | - M Ellis
- District Occupational Therapist
| | | | | | - S Evans
- Senior Lecturer in Statistics
| | | | | | | | | | | | - R D Cohen
- Professor of Medicine, Department of Metabolism and Endocrinology The London Hospital
| |
Collapse
|
50
|
Sardone V, Ellis M, Torelli S, Feng L, Chambers D, Phadke R, Sewry C, Morgan J, Muntoni F. Optimizing dystrophin quantification in DMD and BMD patients: A new semi-automated acquisition and analysis method. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|